The financial continuum and value creation

January 19, 2017 Christoph Graener

Biotech financial markets were buffeted by the winds of macro-economic events in 2016 ranging from the Brexit vote to the unprecedented presidential election in the US. In this new year we will take stock of what we might expect for biotech investment in 2017. Venture capitalists, corporate VCs, crossover investors and I-bankers share their outlooks for the coming year.

Moderator: Ellen B. Corenswet – Covington & Burling LLP

  • Gabriel Cavazos – Leerink Partners LLC
  • Marian T. Nakada – Johnson & Johnson Innovation – JJDC
  • Art Pappas – Pappas Ventures
  • Brian Rosenzweig – Covington & Burling LLP

Previous Article
Partnership and alliance models with tech, pharma, and medical devices

A holistic approach is critical to creating viable solutions for an efficient and effective healthcare syst...

Next Article
Fireside Chat with Bryan Roberts

Gain insights from one of the industry’s most successful investors, featured on the Forbes Midas list eight...